Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

ZEGFROVY

SUNVOZERTINIB

Standard Dose
150MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview ZEGFROVY is listed in Drugs@FDA under application 219839 (NDA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient SUNVOZERTINIB Form and strength TABLET;ORAL - 150MG Sponsor DIZAL JIANGSU Submission history Latest submission status date: 2025-07-02 00:00:00.

Structured Monograph

Clinical summary

Approval overview ZEGFROVY is listed in Drugs@FDA under application 219839 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient SUNVOZERTINIB Form and strength TABLET;ORAL - 150MG Sponsor DIZAL JIANGSU Submission history Latest submission status date: 2025-07-02 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.